ADMA Biologics, Inc. (ADMA)
| Market Cap | 2.83B -22.6% |
| Revenue (ttm) | 519.15M +6.3% |
| Net Income | 182.41M -12.9% |
| EPS | 0.77 -9.4% |
| Shares Out | 221.85M |
| PE Ratio | 16.56 |
| Forward PE | 15.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 609,373 |
| Open | 12.90 |
| Previous Close | 12.73 |
| Day's Range | 12.77 - 13.06 |
| 52-Week Range | 7.21 - 20.46 |
| Beta | 0.66 |
| Analysts | Buy |
| Price Target | 18.00 (+41.01%) |
| Earnings Date | Nov 4, 2026 |
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal anti... [Read more]
Financial Performance
In 2025, ADMA Biologics's revenue was $510.17 million, an increase of 19.63% compared to the previous year's $426.45 million. Earnings were $146.93 million, a decrease of -25.67%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ADMA stock is "Buy." The 12-month stock price target is $18.0, which is an increase of 41.01% from the latest price.
News
Adma Biologics rises 27.3%
Adma Biologics (ADMA) is up 27.3%, or $2.86 to $13.34.
Adma Biologics rises 19.8%
Adma Biologics (ADMA) is up 19.8%, or $2.08 to $12.56.
Adma Biologics price target raised to $18 from $17 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Adma Biologics (ADMA) to $18 from $17 and keeps an Outperform rating on the shares.
Adma Biologics price target raised to $13 from $12 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Adma Biologics (ADMA) to $13 from $12 and keeps a Neutral rating on the shares. Adma Biologics’ Q3 earnings were solid and…
Adma Biologics price target raised to $19 from $18 at Canaccord
Canaccord raised the firm’s price target on Adma Biologics (ADMA) to $19 from $18 and keeps a Buy rating on the shares. The firm said 3Q delivered a much anticipated…
Adma Biologics reports Q3 adjusted basic EPS 23c, consensus 20c
Reports Q3 revenue $141.1M, consensus $138.12M. “Our third quarter results demonstrate ADMA‘s ability to translate accelerating ASCENIV demand into substantial earnings growth,” said Adam Grossman, Pr...
Adma Biologics backs FY26 revenue view at least $530M, consensus $535.35M
Sees FY26 adjusted EBITDA at least $275M. Grossman continued, “Our expanding real-world health outcomes evidence strengthens ASCENIV’s clinical value proposition among medically complex primary immuno...
ADMA Biologics Earnings Call Transcript: Q3 2026
Q3 revenue rose 5% YoY as ASCENIV growth and manufacturing efficiencies lifted gross margin to 71% and adjusted EBITDA to $77.3M. FY26 revenue guidance was maintained, with minimum adjusted earnings guidance raised.
ADMA Biologics Earnings release: Q3 2026
ADMA Biologics released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
ADMA Biologics Quarterly report: Q3 2026
ADMA Biologics has published its Q3 2026 quarterly earnings report on November 4, 2026.
ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37%...
ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board o...
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biol...
Adma Biologics reports Q2 EPS 16c, consensus 16c
Reports Q2 revenue $124.4M, consensus $125.36M. “Our second quarter results reflect strong execution across the business and demonstrate the power of ASCENIV’s growth trajectory,” said Adam Grossman, ...
Adma Biologics backs FY26 revenue view $530M-$560M, consensus $534.37M
Backs FY26 adjusted EBITDA view $265M-$300M. The company said, “The FY2026 outlook continues to reflect sustained competitive dynamics and pricing pressure within the U.S. immune globulin market throu...
ADMA Biologics Earnings Call Transcript: Q2 2026
Q2 2026 saw strong ASCENIV growth, robust cash generation, and margin expansion, with ASCENIV revenue up 24% year-over-year and BIVIGAM stabilizing. Full-year guidance was reiterated, share repurchases continued, and SG-001 development advanced.
ADMA Biologics Earnings release: Q2 2026
ADMA Biologics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
ADMA Biologics Quarterly report: Q2 2026
ADMA Biologics has published its Q2 2026 quarterly earnings report on August 5, 2026.
ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year BIVIGAM Utilization Stabilized with Sequential Improvemen...
ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. , a top complex litigation law firm, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential ...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in ADMA BIOLOGICS, INC. Lawsuit - ADMA
Jerrold V. Grossman, ADMA Biologics co-founder and Vice Chairman, signed annual reports that allegedly concealed channel stuffing and an undisclosed related party distributor operating from ADMA's own...
ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
Conference Call Scheduled for August 5, 2026, at 4:30 p.m. ET RAMSEY, N.J.
Did You Lose Money Investing in ADMA Biologics, Inc. (ADMA)? Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ:...